ArticleJournal of family medicine and primary care2025
SVR timelines in hepatitis - C irrespective of viral genotype: An Indian perspective.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sustained Virologic Response (SVR) refers to successful hepatitis C treatment with undetectable HCV RNA. The duration to achieve SVR is typically 12 weeks globally, though this can vary depending on the viral genotype. Our prime objective in this study was to estimate the mean duration of SVR attainment among treatment-naïve hepatitis C individuals irrespective of viral genotype in India. Materials and Methods: A longitudinal observational study was done on 220 treatment-naïve hepatitis C patients from January 2022 to June 2024 at an Indian tertiary hospital. Patients were treated with 400 mg Sofosbuvir and 100 mg Velpatasvir (SOF/VEL), with HCV RNA measured at 8, 12, and 24 weeks to track SVR attainment. Results and Observations: Out of 220 patients, a total of 212 patients (96.3%) achieved SVR. Of these 84.9% attained SVR in 8 weeks, 11.7% in 12 weeks, and 3.3% in 24 weeks, with a mean duration of 9.22 ± 3.4 weeks. SVR achievement rates for Child-Pugh classes A, B, and C were 98.4%, 90%, and 62.5%, respectively. The majority of Child-Pugh class A patients achieved SVR in just 8 weeks, demonstrating a quicker treatment response. A high degree of concordance is observed between SVR12 and SVR24. Conclusion: Our findings suggest that hepatitis treatment duration varies based on Child-Pugh class and cirrhosis progression indicating the need for individualized treatment plans with tailored therapy durations. As most patients achieved SVR within 8 weeks, a shorter DAA regimen could be effective in the management of hepatitis C, warranting further research to optimize treatment timelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.